Introduction
============

There is currently growing interest in the potential risks associated with assisted reproductive technology (ART). After adjusting for several confounding factors, the risk of numerous adverse outcomes during the perinatal period, including miscarriage, premature birth, low birth weight, intra-uterine growth retardation and gestational hypertension, are higher in *in vitro* fertilization and embryo transfer (IVF-ET) cohorts than for spontaneous pregnancies ([@b1-mmr-21-04-1897]--[@b3-mmr-21-04-1897]). Over the last few years, the early stages of mammalian embryonic development have been shown to be very sensitive to the microenvironment, with long term effects on fetal, postnatal and adult health ([@b4-mmr-21-04-1897]--[@b6-mmr-21-04-1897]). The developmental origins of health and disease hypothesis, based on the evidence that prenatal exposure to modified environmental conditions affects postnatal growth, metabolism and disease susceptibility in adulthood, has been altered to include the preimplantation stages of development ([@b7-mmr-21-04-1897],[@b8-mmr-21-04-1897]). The basal risk associated with pregnancy in a population varies greatly with time and place, and professionals need to be proactive in order to prevent them.

There are an increasing number of well-designed studies that have reported that placental tissues are more sensitive to preimplantation epigenetic disturbances in imprinted genes than embryonic tissues ([@b9-mmr-21-04-1897]--[@b11-mmr-21-04-1897]). This may lead to abnormal placental development and function, with possibly adverse consequences for the developing fetus. In regard to this observation, previous studies have proposed two scenarios to explain why the defects were apparently restricted to the trophectoderm lineage ([@b12-mmr-21-04-1897],[@b13-mmr-21-04-1897]). On the one hand, trophectoderm cells, in contact with the culture medium, are more severely affected by *in vitro* culture, which is responsible for a loss of imprinting in the mid-gestation placenta ([@b14-mmr-21-04-1897]). On the other hand, they are also the first lineage to differentiate in the embryo as trophectoderm stem cells, from which the different cell lines of the future placenta will originate ([@b15-mmr-21-04-1897],[@b16-mmr-21-04-1897]). In addition to culture media composition, which differs from the *in vivo* natural environment despite careful manipulation, *in vitro* production of trophectoderm cells is associated with several environmental stressors, such as oxygen tension, pH and temperature variations during manipulation, light exposure and shear stress linked to repeated pipetting, which may affect placental development and function ([@b17-mmr-21-04-1897],[@b18-mmr-21-04-1897]).

A growing body of evidence in the literature supports the hypothesis that a number of adverse pregnancy outcomes observed after IVF-ET originate from suboptimal placenta function caused by abnormal trophoblastic invasion due to a disturbed dialogue during the early phases of placentation ([@b19-mmr-21-04-1897],[@b20-mmr-21-04-1897]). Fetal-maternal interactions involve a finely balanced synergistic cross-talk of inflammatory and immune modulating factors to allow for maternal immune adaption and tolerance of the semiallogeneic fetus ([@b21-mmr-21-04-1897]). Thus, it is well acknowledged that the placenta functions as an immune-modulating organ that regulates the immune responses of trophoblast cells present both at the implantation site and systemically ([@b22-mmr-21-04-1897]). Increasing evidence indicates that metabolic and proinflammatory conditions affect trophoblastic invasion, as well as placental function and growth in the first trimester of pregnancy long before any phenotypic changes become clinically apparent ([@b23-mmr-21-04-1897]). Furthermore, it is increasingly recognized that trophoblast invasion and placental function early in gestation directly affects fetal development by responding to the environment ([@b24-mmr-21-04-1897]). Therefore, it is important to understand the changes in trophoblastic invasion in placentas subjected to IVF-ET processes; however, little is known concerning this.

In the present study, it was hypothesized that altered gene and protein expression occurs in placental tissues during the first trimester after IVF-ET compared with placental tissues from spontaneous pregnancies. Therefore, the present study analyzed candidate factors related to trophoblast invasion and placental function, to investigate and determine the potential effects of IVF-ET treatment on gene expression in the placenta during the early stages of pregnancy. The aim of the present study was to explore the possible causal relationship between IVF-ET procedures and the higher frequency of adverse pregnancy outcomes. Furthermore, improving the understanding of the placental mechanisms triggered by IVF-ET may be of future value to improve the safety of IVF-ET protocols.

Materials and methods
=====================

### Ethical statement

The research program was approved by the Ethical Committee of Beijing Jishuitan Hospital (permission no. 201703-11) and Peking University Third Hospital (permission no. 2014-075), and all participants provided written informed consent.

### Patients

Between January 2016 and August 2018, twin to singleton fetal reduction was performed in a total of 20 cases at a mean of 49±6 days of pregnancy after IVF-ET treatment (age range, 23--35 years; mean age, 30.8 years) at Beijing Jishuitan Hospital and Peking University Third Hospital. The clinical application of IVF-ET was licensed by the Ministry of Health of The People\'s Republic of China. The control group included 20 cases of unwanted twin pregnancies in the same period (age range, 24--30 years; mean age, 28.9 years). Selection criteria: Patients underwent IVF-ET due to oviductal obstruction; the quality of each male sperm was normal; reasons for fetal reduction in the 20 cases were the patients\' demand. Women who had abnormal menstruation, smoked, drunk alcohol or used any steroid hormone drugs in the previous 3 months were excluded. Clinical data were collected by the Department of Obstetrics and Gynecology at Beijing Jishuitan Hospital and Peking University Third Hospital, and organized in a database. Each of the 20 placental specimens from the IVF-ET group was matched to each of the 20 controls by parity, maternal age and number of gestational weeks.

### Sample collection

All of the fetal reductions were performed by the same senior physician through fetal bud aspiration under B ultrasound guidance. The present study selected 20 cases for villi suction at the same time. The tissues were collected 30--45 days after embryo transfer, which is equivalent to 45--50 days of pregnancy. The control group were diagnosed with early intrauterine pregnancy after bimanual examination, urine pregnancy tests and B ultrasound. All of the patients had regular menstruation and had not taken any steroid hormone drugs in the previous 3 months. The villi were obtained during the conventional artificial abortion operation in the control group. The villi samples were purified immediately from the specimens within 1 h under an inverted microscope. All samples were then floated in ice-cold PBS, and finally stored in liquid nitrogen until future total RNA extraction. Another part of the remaining specimen was immersed in 4% formalin for 24 h at 4°C, and then taken out and rinsed with running water for 30 min. The villi then underwent routine dehydration, wax dipping, embedding and slicing.

### RNA preparation and reverse transcription-quantitative (RT-q)PCR

Tissue homogenization and RNA extraction were performed at CapitalBio Corporation. Homogenization of the tissue and isolation of the total RNA were performed using TRIzol^®^ (Invitrogen; Thermo Fisher Scientific, Inc.) according to the standard method. The RNA, extracted with ribosomal 28S and 18S RNA with a ratio of intensities of 1.5--1.8:1, was used for RT-qPCR analysis. Complementary DNA (cDNA) was generated using a PrimeScript II 1st Strand cDNA synthesis kit (Takara Biotechnology Co., Ltd.) using random or oligo(dT) primers for 15 min at 37°C, 5 sec at 85°C. qPCR was performed using a SYBR-Green PCR Master mix (Takara Biotechnology Co., Ltd.). Specific forward and reverse primer pairs were designed for each gene and are listed in [Table I](#tI-mmr-21-04-1897){ref-type="table"}. Amplification was performed using the following thermocycling conditions: 94°C for 5 min; 95°C for 30 sec, 62°C for 30 sec and 72°C for 30 sec (35 cycles); and a final extension at 72°C for 10 min. To minimize variation in the RT reaction, all the RNA samples from a single experimental setup were reverse transcribed simultaneously ([@b25-mmr-21-04-1897]). For the *in vitro* experiments, the relative expression of mRNA was calculated using the comparative quantitative cycle (2^−∆∆Cq^) method ([@b26-mmr-21-04-1897],[@b27-mmr-21-04-1897]) and normalized to the internal control human gene GAPDH ([@b28-mmr-21-04-1897]).

### Immunohistochemistry (IHC)

Placental tissues were embedded in paraffin and sectioned for IHC. After drying in an oven at 60°C for 2 h, tissue sections (4 µm) were deparaffinized in xylene and rehydrated through a descending alcohol series. Endogenous peroxides were quenched by immersing the tissue sections in 3% hydrogen peroxide in methanol for 10 min at room temperature. After heat induction in citric acid for 15 min and blocking with 1% bovine serum albumin (Sigma-Aldrich; Merck KGaA) for 20 min at 4°C, the slides were incubated at 4°C overnight with polyclonal antibodies. The following primary antibodies (1:50 dilution unless otherwise specified) were used: α-fetoprotein (AFP; cat. no. ZA-0612; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.; OriGene Technologies, Inc.), vascular endothelial growth factor (VEGF; cat. no. ZM-0265; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.; OriGene Technologies, Inc.), transferrin (TF; cat. no. TA500848; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.; OriGene Technologies, Inc.), tubulin β1 class VI (TUBB1; cat. no. TA506805; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.; OriGene Technologies, Inc.), metallothionein 1G (MT1G cat. no. LS-B13009; LifeSpan BioSciences), BCL2 (cat. no. ZM-0010; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.; OriGene Technologies, Inc.), glial cells missing transcription factor 1 (GCM1; 1:100 dilution; cat. no. ab187860; Abcam), epidermal growth factor receptor (EGFR; cat. no. ZM-0093; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.; OriGene Technologies, Inc.), PTEN (cat. no. ZA-0635; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.; OriGene Technologies, Inc.) and leukocyte associated immunoglobulin like receptor 2 (LAIR2; 1:100 dilution; cat. no. ab183145; Abcam). After washing with PBS, the sections were subsequently incubated with SignalStain^®^ Boost IHC detection reagent (horseradish peroxidase, rabbit; cat. no. 8114P; Cell Signaling Technology, Inc.) for 1 h at room temperature. Negative controls received PBS instead of primary antibodies. Staining was completed by incubation with diaminobenzidine tetrahydrochloride for 4 min at room temperature, and tissues were counterstained with hematoxylin for 5 min at room temperature. Immunohistochemical staining of samples and negative controls was simultaneously executed.

### Assessment of the immunohistochemical staining results

The immunohistochemical staining of the villi in the slices was observed using optical microscopy (Eclipse 80i; Nikon Corporation). The positive reaction products were brown-yellow granules. Image-Pro Plus analysis software version 6.0 (Media Cybernetics, Inc.) was used on the immunohistochemical data for semi-quantitative analysis of the staining intensity. Images were viewed at magnification, ×400 using the double-blind method and ordinary illumination, and 5 areas from each slice were randomly selected on the high-resolution monitor. The mean optical density (MOD) of positive expression was measured in each area, and the mean was calculated to obtain a MOD that was representative of the slice. A total of 5 slices from each sample were assessed, and the mean of each group was calculated.

### Gene expression data analysis

The Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.kegg.jp/> or <http://www.genome.jp/kegg/>) ([@b29-mmr-21-04-1897]) Orthology-Based Annotation System (KOBAS; version 2.0; <http://kobas.cbi.pku.cn>) was employed to identify enriched KEGG pathways based on an adjusted P-value. Search Tool for the Retrieval of Interacting Genes (STRING; version 11.0) software was used to draw the genetic interaction network (<https://string-db.org/>). The false discovery rate (FDR) was provided by KEGG.

### Statistical analysis

SPSS software (version 21.0; IBM Corp.) was used for the collection, processing and statistical analysis of the data. The data were expressed as the mean ± standard error. Statistical analysis was performed using independent samples t-tests for comparison of the means. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Characteristics of the patients

There were no statistical differences between the two groups of women in terms of age, gestational age and body mass index ([Table II](#tII-mmr-21-04-1897){ref-type="table"}).

### mRNA expression

Based on their biological processes mostly related to placental functions, 10 genes were selected and their mRNA expression was measured in the placenta using RT-qPCR. The results of RT-qPCR demonstrated that the placental mRNA expression levels of AFP, VEGF and TF were significantly increased in the IVF-ET group compared with the control group ([Fig. 1](#f1-mmr-21-04-1897){ref-type="fig"}). In addition, the placental mRNA expression of TUBB1, MT1G, BCL2, GCM1, EGFR, PTEN and LAIR2 was significantly decreased in the IVF-ET group compared with in the control as analyzed by RT-qPCR. Among the 10 tested genes, the present study observed a significant concordance with the results observed in IHC.

### IHC

To verify the differentially expressed gene products in the human placenta, the present study localized protein expression via IHC. All selected proteins were located in either the cytoplasm or cytomembrane of syncytiotrophoblasts and cytotrophoblast cells in the placental villi tissues obtained from both the IVF-ET and control groups. The protein expression levels of AFP, VEGF and TF in the placental villi of the IVF-ET group were significantly higher than those in the control group ([Fig. 2](#f2-mmr-21-04-1897){ref-type="fig"}). The protein expression of TUBB1, MT1G, BCL2, GCM1, EGFR, PTEN and LAIR2 in the placental villi of the IVF-ET group was lower than those in the control group ([Figs. 2](#f2-mmr-21-04-1897){ref-type="fig"} and [3](#f3-mmr-21-04-1897){ref-type="fig"}). The products of AFP, VEGF and TF were expressed in both villous syncytiotrophoblasts and cytotrophoblast cells in the IVF-ET group, whereas there was only low expression in the villous syncytiotrophoblasts in the control group ([Fig. 2](#f2-mmr-21-04-1897){ref-type="fig"}). TUBB1 was observed in the cytoplasm and cytomembrane of villous cytotrophoblast cells and syncytiotrophoblasts in the IVF-ET group, whereas there was more diffuse TUBB1 staining in the control group ([Fig. 2](#f2-mmr-21-04-1897){ref-type="fig"}). MT1G was poorly expressed in villous cytotrophoblast cells and syncytiotrophoblasts in the IVF-ET group, and it was highly expressed in vascular endothelial cells and syncytiotrophoblasts in the control group ([Fig. 2](#f2-mmr-21-04-1897){ref-type="fig"}). BCL2 was widely distributed in the cytoplasm and cytomembrane of villous syncytiotrophoblasts and cytotrophoblast cells during early pregnancy. In the IVF-ET group, low expression of BCL2 was observed in both types of cells ([Fig. 3](#f3-mmr-21-04-1897){ref-type="fig"}). GCM1 was located in the plasma of the cytotrophoblast cells and syncytiotrophoblasts of early villi, and it was poorly expressed in all cell types unlike the other selected gene products ([Fig. 3](#f3-mmr-21-04-1897){ref-type="fig"}). EGFR was found in the plasma and cytomembrane of syncytiotrophoblasts and cytotrophoblast cells, and it was more strongly expressed on the surface of syncytiotrophoblasts in the control group compared with the IVF-ET group ([Fig. 3](#f3-mmr-21-04-1897){ref-type="fig"}). PTEN and LAIR2 were widely expressed in the cytoplasm and cytomembrane of villous syncytiotrophoblasts and cytotrophoblast cells in early pregnancy. In the IVF-ET group, lower expression of PTEN and LAIR2 was observed in both types of cells compared with the control group ([Fig. 3](#f3-mmr-21-04-1897){ref-type="fig"}).

### Quantitative analysis of immunohistochemical images

After staining, photographs of 5 random fields for each placental villus were taken, and the MOD of the photographs was calculated ([Table SI](#SD1-mmr-21-04-1897){ref-type="supplementary-material"}). The expression of AFP, VEGF and TF in the placental villi of the IVF-ET group was significantly higher than that observed in the control group (P\<0.05; [Table SI](#SD1-mmr-21-04-1897){ref-type="supplementary-material"}). However, TUBB1, MT1G, BCL2, GCM1, EGFR, PTEN and LAIR2 expression was significantly lower in the placental villi of the IVF-ET group when compared with the control group (P\<0.05; [Fig. 4](#f4-mmr-21-04-1897){ref-type="fig"}; [Table SI](#SD1-mmr-21-04-1897){ref-type="supplementary-material"}).

### KEGG pathway and network analysis

The KEGG pathway analysis of differentially expressed genes using KOBAS revealed that the observed genes participated in \>25 statistically overrepresented pathways. These 10 differentially expressed genes participated in multiple signaling pathways, including EGFR tyrosine kinase inhibitor resistance (n=4; FDR: P=2.78×10^−8^; [Fig. 5A](#f5-mmr-21-04-1897){ref-type="fig"}), hypoxia-inducible factor-1 signaling pathway (n=4; FDR P=6.92×10^−8^), focal adhesion (n=4; FDR P=9.60×10^−7^), microRNAs in cancer (n=4; FDR P=2.89×10^−6^) and PI3K-Akt signaling pathway (n=4; FDR P=7.05×10^−6^; [Table III](#tIII-mmr-21-04-1897){ref-type="table"}). The 10 differentially expressed genes were also mapped using STRING online software ([Fig. 5B](#f5-mmr-21-04-1897){ref-type="fig"}). A network was built based on evidence from experimental interactions and databases. A total of 5 interactions between proteins encoded by differentially expressed genes were observed in STRING ([Fig. 5B](#f5-mmr-21-04-1897){ref-type="fig"}). Bioinformatics analyses of the data suggested that various molecular and cellular functions were affected, and show their link to placental development and functions in the first trimester.

Discussion
==========

The placenta in early pregnancy performs important functions, such as adhesion, differentiation, immune tolerance, invasion, angiogenesis, barrier, nutrition and spiral artery remodeling ([@b30-mmr-21-04-1897]). There has been previous literature on the development and function of the placenta; especially the development of gene chips, making it possible to detect early, middle and late placental genes ([@b31-mmr-21-04-1897],[@b32-mmr-21-04-1897]). As the changes in placental function are related to pregnancy complications ([@b31-mmr-21-04-1897]), the current research hotspot in the field of obstetrics is to find the early pathological changes of the placenta as fast as possible, and develop early diagnosis and prevention methods. At the same time, it has been found that placental function is closely related to the placental origins of adulthood chronic disease, including metabolic, immune and cardiovascular diseases ([@b33-mmr-21-04-1897]). Therefore, the existing literature and research concluded that the early, middle and late stages of placental development exhibit distinct differences in physiological functions and gene expression, and understanding the effects of pathogenic factors on early placental development, function and gene expression contributes to early diagnosis and medical intervention ([@b34-mmr-21-04-1897]). A growing body of evidence supports the hypothesis that various adverse pregnancy outcomes observed after ART originate from suboptimal placentation caused by abnormal trophoblast function ([@b2-mmr-21-04-1897],[@b3-mmr-21-04-1897]). In humans, after adjusting for several confounding factors, the risk of spontaneous abortion is higher in ART cohorts than for spontaneous pregnancies ([@b35-mmr-21-04-1897]). Notably, human studies have reported an increased risk of gestational hypertension, preeclampsia, placenta previa and placental abruption in IVF-ET groups ([@b36-mmr-21-04-1897],[@b37-mmr-21-04-1897]). The placental phenotype is responsive to nutritional conditions. When fetal nutrient availability is compromised, it adapts to maximize the nutrient transfer capacity ([@b38-mmr-21-04-1897]). These compensatory mechanisms may start from the blastocyst stage, within extra-embryonic lineages ([@b39-mmr-21-04-1897]--[@b41-mmr-21-04-1897]). Thus, the aim of the present study was to determine whether there was evidence of functional placental pathology in the first 6--7 weeks of pregnancy after IVF-ET by detecting the expression of candidate genes related to trophoblastic functions.

In the present study, a number of important factors associated with trophoblast cell invasion and placenta formation were selected, and their mRNA and protein expression levels were compared between the IVF-ET group and in those that conceived naturally. The RT-qPCR data revealed that the mRNA expression of AFP, VEGF and TF was upregulated, and TUBB1, MT1G, BCL2, GCM1, EGFR, PTEN and LAIR2 were downregulated in placentas that had undergone IVF-ET treatment, when compared with placentas from natural pregnancies. To identify differentially expressed gene products in the human placenta, these candidate factors were selected for IHC analysis, and the results were consistent with those of RT-qPCR. A number of studies have previously examined and identified altered gene expression in placental tissues after IVF-ET treatment ([@b39-mmr-21-04-1897]--[@b41-mmr-21-04-1897]). One study investigated global gene expression in three term placentas from IVF-ET pregnancies compared with 3 placentas from spontaneous pregnancies; they reported 18 differentially expressed genes, and classified them according to their role in biological processes associated with the immune response, transmembrane transport, metabolism, oxidative stress and cell differentiation ([@b42-mmr-21-04-1897]). Furthermore, a previous study on the placental transcriptome after IVF-ET in animals also revealed comparable results ([@b43-mmr-21-04-1897]). The present study used embryo villi in the first trimester and found a variety of genetic changes in trophoblastic function. These results suggested that early placental tissues may undergo extensive genetic and functional changes. Previous animal experimental research supports the hypothesis of the present study ([@b44-mmr-21-04-1897]--[@b46-mmr-21-04-1897]). It was previously reported that a smaller quantity of trophectoderm cells developed in mouse blastocysts from *in vitro* culture than in naturally conceived blastocysts ([@b47-mmr-21-04-1897],[@b48-mmr-21-04-1897]). With regard to *in vitro* results, placentas were found to be smaller and lighter than control placentas at early gestation, and heavier at late gestation in IVF-ET cases ([@b49-mmr-21-04-1897]). This supports the hypothesis that initial environmental disturbances could trigger placental adaptive responses during pregnancy. Therefore, studying changes in early placental gene expression could be useful in demonstrating the effects of IVF-ET on placental development and function, as well as placenta-derived diseases.

The present study demonstrated that mRNA and protein expression of AFP, VEGF and TF was upregulated in placentas after IVF-ET treatment compared with placentas from natural pregnancies. Under normal circumstances, the expression of AFP in trophoblast cells is weak, and it is mainly located in discontinuous regions at junctions between two villi ([@b50-mmr-21-04-1897]). AFP is derived from trophoblast cells at the maternal-fetal interface in early pregnancy; it is important in regulating angiogenesis, cell growth, inflammatory responses and immune tolerance, as well as participating in important physiological events in the first 3 months of pregnancy ([@b51-mmr-21-04-1897],[@b52-mmr-21-04-1897]). The main role of AFP is to facilitate the development of the placenta, and the compensatory mechanism is only initiated when blood vessels have developed abnormally. AFP is strongly expressed by villous trophoblastic cells in anembryonic pregnancy compared with the normal group ([@b53-mmr-21-04-1897]). The present study showed that the expression of AFP in the villous tissue of the IVF-ET group was higher than in the control group. This suggested that the upregulation of AFP in the IVF-ET group may indicate a delay of embryo/placenta development rather than disruption of the placenta. This may support our hypothesis that, after IVF-ET, the vascular development of trophoblasts declines, and so there is a compensatory upregulation of AFP in order to ensure normal vascular development in the placenta during the second and third trimesters, as well as to maintain the normal function of the placenta, and protect the exchange of substances and nutrients between the mother\'s womb and the fetus. A similar mechanism is also hypothesized to occur in regard to VEGF and TF. VEGF improves angiogenesis and ensures normal vascular development in IVF-ET placentas in the first trimester ([@b54-mmr-21-04-1897]). TF is a glycoprotein produced by placental cells that is important in respiration and oxygen transport; therefore, it is required for the effective transport of iron ions throughout the placenta and fetus ([@b55-mmr-21-04-1897]). Abnormal expression of AFP, VEGF and TF early in placental development doubles the risk of preterm delivery, while in the fetus it may contribute to the development of cardiovascular disease in adulthood ([@b56-mmr-21-04-1897]). Thus showing how important these factors are during pregnancy.

In the present study, the mRNA and proteomic expression of TUBB1, MT1G, BCL2, GCM1, EGFR, PTEN and LAIR2 were downregulated in the placentas that had undergone IVF-ET treatment when compared with the control. TUBB1 is a major component of microtubules, which are important cellular matrix structures that are essential for processes such as mitosis, intracellular transportation, cell motility and stability ([@b57-mmr-21-04-1897]). The maintenance and morphology of an integral vascular system is highly reliant on an intact endothelial cytoskeleton ([@b58-mmr-21-04-1897]). It has been hypothesized that impairment of maternal spiral artery remodeling and fetal villi circulation is a leading cause of preeclampsia ([@b59-mmr-21-04-1897]). MT1G expression in the placenta is important to the structural integrity and function of the placenta ([@b60-mmr-21-04-1897]). Although it does not ameliorate the oxidative stress-induced perturbation of a number of trophoblastic functions, MT1G expression is critical for protecting these similar cells against severe oxidative stress-induced apoptosis ([@b61-mmr-21-04-1897]). BCL2 is considered to be an antiapoptotic factor that is responsible for inhibiting apoptosis in the placenta ([@b62-mmr-21-04-1897]). Apoptosis plays a central role in placental development, homeostasis and immune defense in the placenta, and it is strictly controlled in part by members of the BCL2 family ([@b63-mmr-21-04-1897]). Previous independent studies have reported an association between reduced levels of BCL2 and the incidence of premature ruptures in the membranes and the pathogenesis of preterm birth ([@b64-mmr-21-04-1897],[@b65-mmr-21-04-1897]). GCM1 is a key transcription factor in placental development, and is critical for trophoblastic fusion, placental vasculogenic and maternal vascular remodeling ([@b66-mmr-21-04-1897]). Decreased expression of GCM1, as well as its target genes, has been observed in preeclampsia and trophoblast cells under hypoxia, therefore indicating that GCM1 activity may contribute to the pathogenesis of preeclampsia ([@b67-mmr-21-04-1897]). The binding of EGF and EGFR on trophoblast cells has been shown to stimulate intracellular tyrosine kinase activity and trigger phosphorylation reactions, thereby increasing the nutritional intake of villi, promoting the proliferation and differentiation of the placenta, promoting trophoblastic cell survival and increasing the secretion of placenta ([@b68-mmr-21-04-1897]). A previous study showed that the expression of EGFR was significantly lower in a group of preeclampsia and intrauterine growth retardation cases than in placentas from normal pregnancies ([@b69-mmr-21-04-1897]). PTEN was originally identified as a tumor suppressor and upregulation of PTEN has been shown to increase cell apoptosis ([@b70-mmr-21-04-1897]). In preeclampsia cases, it has been reported that PTEN expression is increased in the placenta, which also leads to increased apoptosis, as well as impaired migration and invasion abilities of trophoblastic cells ([@b71-mmr-21-04-1897]). In the present study, the expression of PTEN in IVF-ET samples was significantly lower than in the control group, which could indicate that PTEN is involved in the adaptive response to placental disturbance. LAIR2 may function to maintain the activation of decidual leukocytes, particularly NK cells at sites of trophoblast invasion ([@b72-mmr-21-04-1897]). Decreased LAIR2 expression may decrease the decidual tolerance of trophoblasts and then result in shallow invasion, fostering the development of preeclampsia and other complications potentially associated with abnormal trophoblast invasion, such as fetal growth restriction and preterm birth ([@b73-mmr-21-04-1897]).

The KEGG pathway analysis of differentially expressed genes revealed \>25 pathways that were disrupted in the first trimester placenta derived from IVF-ET. Taking the EGFR tyrosine kinase inhibitor resistance-signaling pathway in [Fig. 5A](#f5-mmr-21-04-1897){ref-type="fig"} as an example, differentially expressed genes and protein molecules interfere with the differentiation, growth, survival and angiogenesis of placental trophoblast cells. Further analysis showed that these pathways are widely involved in key events of early placental development and function, and previous research has shown that disruption of these pathways can lead to adverse outcomes ([@b68-mmr-21-04-1897]). All ten genes were used as input for STRING analysis and a network was built based on high confidence evidence from experimental protein-protein interactions. Parallel approaches using STRING analysis resulted in a total of five interactions between proteins encoded by differentially expressed genes. The present results suggested that IVF-ET treatment and associated processes may interfere with placental formation and function, resulting in placenta-related adverse pregnancy outcomes. However, in the majority of cases, pregnancies achieved via IVF-ET are able to continue without obvious immediate adverse outcomes. This supports the hypothesis that initial defective trophoblast functions could trigger placental adaptive responses during pregnancy. The present study showed that IVF-ET results in suboptimal placental conditions in the first trimester but counterbalancing mechanisms also occurred. The same phenomenon was previously verified in animal experiments. During early pregnancy in mice, IVF-ET placentas and embryos were smaller than those in the naturally conceived group ([@b74-mmr-21-04-1897]). At a later stage, trophoblast cell proliferation was greater in IVF-ET placentas than in the control, in both the labyrinth and spongiotrophoblast layer ([@b75-mmr-21-04-1897]). By birth, IVF-ET placentas were found to be heavier than the control group ([@b76-mmr-21-04-1897]). Likewise, placentas in humans following IVF-ET were overrepresented in the highest quartile of weight, and the placenta weight/birth weight ratio was frequently higher even after adjusting for potential confounding factors ([@b77-mmr-21-04-1897]). A larger placenta is not necessarily synonymous with a higher efficiency in oxygen and nutrient transfer. In response to certain stress factors that modify the early environment of IVF-ET, it is hypothesized that the placenta could amplify these compensatory mechanisms up to a certain point. In the present results, these modified genes and proteins after IVF-ET could have consequences in infancy and adulthood, particularly in relation to metabolic and cardiovascular conditions. In addition, the size and shape of the placenta have been previously associated with life expectancy and risk for coronary heart disease ([@b78-mmr-21-04-1897]). Notably, the available data on the long-term follow-up of IVF-ET children has revealed cardiovascular and metabolic risk factors ([@b79-mmr-21-04-1897]).

A limitation of the present study was the small number of samples investigated in each group. These samples were selected from a cohort of 40 samples collected prospectively for this work. Although the sample size was small, only significant levels of variance in gene and protein expression levels were reported. These data allow future work to be directed towards altered placental formation and function, resulting in placenta-related adverse pregnancy outcomes in IVF-ET cases. Another limitation of the present study is the small number of genes and proteins. Due to the limited number of specimens, this study also lacked experiments to validate the RT-qPCR and IHC, and did not verify the function of candidate genes in cell lines. Additional studies are needed to address these limitations. Further work is needed to determine the biological plausibility of the variations in gene expression, although if results of the present study are consistent across future studies and translate to protein expression in maternal serum, they may still be valuable in predicting abnormal outcomes in the later stages of pregnancy.

The present study indicated the differential gene and protein expression observed between placentas after IVF-ET and those from naturally conceived cases. In the majority of cases, efficient compensatory mechanisms ensure normal fetal growth up to term. When compensation mechanisms are unbalanced, pathological features such as miscarriages, low birth weight or preeclampsia can occur. However, whether this compensation could be a risk factor for certain diseases later in life remains to be determined. The present results will enable researchers to focus on a small number of key genes and proteins that require further investigation. Future studies with a larger sample size focusing on additional molecular mechanisms and proteins may lead to the development of molecular tests to predict adverse outcomes in the first trimester. Understanding the impact on the placenta triggered by IVF-ET will increase the safety of future IVF-ET protocols.
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![Results of reverse transcription-quantitative PCR analysis of selected genes from placentas derived from IVF-ET manipulation and natural pregnancies. \*P\<0.05, \*\*P\<0.01. IVF-ET, *in vitro* fertilization and embryo transfer; AFP, α-fetoprotein; VEGF, vascular endothelial growth factor; TF, transferrin; TUBB1, tubulin β1 class VI; MT1G, metallothionein 1G; GCM1, glial cells missing transcription factor 1; EGFR, epidermal growth factor receptor; LAIR2, leukocyte associated immunoglobulin like receptor 2.](MMR-21-04-1897-g00){#f1-mmr-21-04-1897}

![Immunohistochemistry of AFP, VEGF, TF, TUBB1 and MT1G to detect cellular localization. All proteins were found located in either the cytoplasm or cytomembrane of syncytiotrophoblasts and cytotrophoblast cells in the placental villi tissues obtained from control group. Scale bar, 10 µm. AFP, α-fetoprotein; VEGF, vascular endothelial growth factor; TF, transferrin; TUBB1, tubulin β1 class VI; MT1G, metallothionein 1G; IVF-ET, *in vitro* fertilization and embryo transfer.](MMR-21-04-1897-g01){#f2-mmr-21-04-1897}

![Immunohistochemistry of BCL2, GCM1, EGFR, PTEN and LAIR2 to detect cellular localization. All proteins were located in either the cytoplasm or cytomembrane of syncytiotrophoblasts and cytotrophoblast cells in placental villi tissues obtained from the control group. Scale bar, 10 µm. GCM1, glial cells missing transcription factor 1; EGFR, epidermal growth factor receptor; LAIR2, leukocyte associated immunoglobulin like receptor 2; IVF-ET, *in vitro* fertilization and embryo transfer.](MMR-21-04-1897-g02){#f3-mmr-21-04-1897}

![Mean optical density of the positive expression of the selected genes in the two groups. (A) Mean optical density of AFP, VEGF, TF, TUBB1 and MT1G in the placental villus derived from IVF-ET and control group. (B) Mean optical density of BCL2, GCM1, EGFR, PTEN and LAIR2 in the placental villus derived from IVF-ET and control group.\*P\<0.05, \*\*P\<0.01. IVF-ET, *in vitro* fertilization and embryo transfer; AFP, α-fetoprotein; VEGF, vascular endothelial growth factor; TF, transferrin; TUBB1, tubulin β1 class VI; MT1G, metallothionein 1G; GCM1, glial cells missing transcription factor 1; EGFR, epidermal growth factor receptor; LAIR2, leukocyte associated immunoglobulin like receptor 2.](MMR-21-04-1897-g03){#f4-mmr-21-04-1897}

![Schematic representation and interaction network of differentially expressed genes in the placenta affected by IVF-ET in the first trimester. (A) Schematic representation showing a number of the differentially expressed genes in the placenta affected by IVF-ET. Dark green represents downregulation; light green represents no significant change. (B) Gene interaction networks of differentially expressed genes in the placenta affected by IVF-ET. All 10 differentially expressed genes were used as input for Search Tool for the Retrieval of Interacting Genes analysis and a network was built. Differentially expressed genes based on high confidence are shown. IVF-ET, *in vitro* fertilization and embryo transfer; AFP, α-fetoprotein; VEGF, vascular endothelial growth factor; TF, transferrin; TUBB1, tubulin β1 class VI; MT1G, metallothionein 1G; GCM1, glial cells missing transcription factor 1; EGFR, epidermal growth factor receptor; LAIR2, leukocyte associated immunoglobulin like receptor 2.](MMR-21-04-1897-g04){#f5-mmr-21-04-1897}

###### 

Primer sequences used for reverse transcription-quantitative PCR amplification and the conditions.

  Gene    Primer sequence (5′-3′)      Annealing temperature (°C)   Cycles   Product size (bp)
  ------- ---------------------------- ---------------------------- -------- -------------------
  AFP     F: TCCAGCCAAAGTGAAGAGGG      59                           35       471
          R: CAAGCTGCTITCTCTTAATTC                                           
  GCM1    F: GGCCGATCCAGCTATATCAA      58                           42       254
          R: CTGGGGTGCACATAGTGAAA                                            
  LAIR2   F: GCCATGTCTCCACACCTC        60                           45       428
          R: GAAGTTCACAAGACGGGAGG                                            
  PTEN    F: CGACGGGAAGACAAGACAGTAG    60                           42       330
          R: GCTAGCCTCTGGATTTGACG                                            
  BCL2    F: CAGATGGCAAATGACCAGCAGA    58                           38       375
          R: TGGCAGGATAGCAGCACAGGAT                                          
  TF      F: GCAATGGGCAGATAGAGTGT      60                           40       256
          R: GTGTTCTTTCGTTCGTGTT                                             
  MT1G    F: TCGCTTGAGATCTCCAGCCTTAC   59                           42       280
          R: ACATCTGGGAGAAGAGCTGTCC                                          
  EGFR    F: GGACTCTGGATCCCAGAAGGTG    58                           45       332
          R: GCTGGCCATCACGTAGGCTT                                            
  VEGF    F: ATGAACTTTCTCTGCTGTCTGG    57                           35       354
          R: TCACCGCCTCGGCTTGTCACA                                           
  TUBB1   F: TTCCAGCTGACCCACTCTCT      60                           42       434
          R: ACAGGGCCTCGTI\'ATCAATG                                          
  GAPDH   F: GGTGCTGAGTATGTCGTGGAGT    58                           42       212
          R: CAGTCTTCTGAGTGGCAGGAT                                           

F, forward; R, reverse; AFP, α-fetoprotein; VEGF, vascular endothelial growth factor; TF, transferrin; TUBB1, tubulin β1 class VI; MT1G, metallothionein 1G; GCM1, glial cells missing transcription factor 1; EGFR, epidermal growth factor receptor; LAIR2, leukocyte associated immunoglobulin like receptor 2.

###### 

Characteristics of the patients in the two groups.

  Characteristic          IVF-ET group (n=20)   Control group (n=20)   T-statistic   P-value
  ----------------------- --------------------- ---------------------- ------------- ---------
  Mean age (years)        30.66±3.76            28.86±3.45             0.823         0.425
  Gestational age (day)   49.44±3.14            49.35±3.23             0.637         0.529
  Gravidity               1.10±1.21             2.21±0.89              0.858         0.437
  BMI (kg/m^2^)           23.33±3.17            22.99±2.35             1.311         0.263

IVF-ET, *in vitro* fertilization and embryo transfer.

###### 

Analysis of differentially expressed genes by KEGG signaling pathway.

  Term                                                   Input number   P-value       Input
  ------------------------------------------------------ -------------- ------------- ---------------------------------------------------------------------
  EGFR tyrosine kinase inhibitor resistance              4              2.78×10^−8^   ENSG00000146648\|ENSG00000112715\|ENSG00000171791\|ENSG00000171862
  HIF-1 signaling pathway                                4              6.92×10^−8^   ENSG00000146648\|ENSG00000112715\|ENSG00000171791\|ENSG00000091513
  Focal adhesion                                         4              9.60×10^−7^   ENSG00000146648\|ENSG00000112715\|ENSG00000171791\|ENSG00000171862′
  MicroRNAs in cancer                                    4              2.89×10^−6^   ENSG00000146648\|ENSG00000112715\|ENSG00000171791\|ENSG00000171862
  Prostate cancer                                        3              5.98×10^−6^   ENSG00000146648\|ENSG00000171791\|ENSG00000171862
  PI3K-Akt signaling pathway                             4              7.05×10^−6^   ENSG00000146648\|ENSG00000112715\|ENSG00000171791\|ENSG00000171862
  Pathways in cancer                                     4              1.27×10^−5^   ENSG00000146648\|ENSG00000112715\|ENSG00000171791\|ENSG00000171862
  Bladder cancer                                         2              1.31×10^−4^   ENSG00000146648\|ENSG00000112715
  Mineral absorption                                     2              2.12×10^−4^   ENSG00000091513\|ENSG00000125144
  Endometrial cancer                                     2              2.23×10^−4^   ENSG00000146648\|ENSG00000171862
  Glioma                                                 2              3.32×10^−4^   ENSG00000146648\|ENSG00000171862
  Pancreatic cancer                                      2              3.42×10^−4^   ENSG00000146648\|ENSG00000112715
  Central carbon metabolism in cancer                    2              3.53×10^−4^   ENSG00000146648\|ENSG00000171862
  Melanoma                                               2              3.92×10^−4^   ENSG00000146648\|ENSG00000171862
  Gap junction                                           2              5.61×10^−4^   ENSG00000146648\|ENSG00000101162
  Small cell lung cancer                                 2              5.62×10^−4^   ENSG00000171791\|ENSG00000171862
  Endocrine resistance                                   2              7.13×10^−4^   ENSG00000146648\|ENSG00000171791
  AGE-RAGE signaling pathway in diabetic complications   2              7.63×10^−4^   ENSG00000112715\|ENSG00000171791
  Sphingolipid signaling pathway                         2              1.08×10^−4^   ENSG00000171791\|ENSG00000171862
  FoxO signaling pathway                                 2              1.29×10^−4^   ENSG00000146648\|ENSG00000171862
  Hepatitis B                                            2              1.55×10^−4^   ENSG00000171791\|ENSG00000171862
  Proteoglycans in cancer                                2              3.12×10^−4^   ENSG00000146648\|ENSG00000112715
  Rap1 signaling pathway                                 2              3.23×10^−4^   ENSG00000146648\|ENSG00000112715
  Ras signaling pathway                                  2              3.67×10^−4^   ENSG00000146648\|ENSG00000112715
  Cytokine-cytokine receptor interaction                 2              4.79×10^−4^   ENSG00000146648\|ENSG00000112715

EGFR, epidermal growth factor receptor; HIF-1, hypoxia-inducible factor 1; AGE, advanced glycation endproducts; RAGE, receptor for AGE; FoxO, forkhead box O; Rap1, Ras-related protein 1.
